ClinicalTrials.gg
CompletedNCT03938246Updated Dec 19, 2024Results posted

Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

A Phase 2 interventional study of TVB-2640 25 mg (US) and TVB-2640 50 mg (US) in MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis), sponsored by Sagimet Biosciences Inc.. Completed at 23 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-19.

Sponsored by Sagimet Biosciences Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
142
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.

Enrollment
114th of 460
142 · median 56
Started
2019
with 61 others
Phase 2
192 of 547
15 open now
Registered
286th of 547
by date

Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 114th largest by enrollment of the 460 interventional ones that give a count, is one of 62 that started in 2019, is one of 192 in phase 2, and was the 286th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 323 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 220 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 125 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2 multi-center, randomized, single-blind, placebo-controlled study to evaluate the safety and efficacy of TVB-2640 in subjects with non-alcoholic steatohepatitis (NASH), a type of fatty liver disease. Subjects will be randomly assigned to 1 of 2 treatment groups (TVB-2640 at one of three doses or placebo). Following randomization, subjects will begin the 12-week treatment period and will receive once daily TVB-2640 or placebo.

03

Conditions studied

  • MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)

Keywords

  • NASH
  • Non-Alcoholic Steatohepatitis
  • Fatty Liver Disease
  • Fatty Liver
  • Liver Diseases
  • FASN
  • Fatty Acid Synthase Inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged ≥ 18 years with a (BMI) ≤40 kg/m2.
  2. Prior liver within 24 months of randomization with fibrosis Stage 1 to 3 and a non-alcoholic fatty liver disease (NAFLD) activity score (NAS) of ≥ 4 with at least a score of 1 in each of the following NAS components:

    • Steatosis
    • Ballooning degeneration
    • Lobular inflammation

AND

  • Confirmation of ≥ 8% liver fat content on MRI-PDFF.

OR, if prior biopsy is not available:

  • Either overweight or obese or diabetic or ≥ 30 U/L or fatty liver on ultrasound and at least one more feature of metabolic syndrome by Adult Treatment Panel III (ATP III) criteria.

AND

  • Magnetic resonance elastography (MRE) ≥ 2.5 kPa and MRI-PDFF ≥ 8% during screening.

Exclusion criteria

Exclusion Criteria:

Subjects meeting any of the following criteria are not eligible for enrollment in the study.

  1. History of significant alcohol consumption for a period of more than 3 consecutive months within 1 year prior to screening.

    Note: Significant alcohol consumption is defined as average of > 20 g/day in female subjects and > 30 g/day in male subjects.

  2. Type 1 diabetes.
  3. Uncontrolled Type 2 diabetes defined as:

    • ≥ 9.5% during screening. (Subjects with HbA1c ≥ 9.5% may be rescreened).
    • Basal insulin dose adjustment > 10% within 60 days prior to enrollment.
    • Requirement for glucagon-like peptide analogue or a complex oral anti-diabetic (OAD) regimen (3 or more OADs) within 6 months of screening.
    • History of severe hypoglycemia (symptomatic hypoglycemia requiring outside assistance to regain normal neurologic status) within the previous year.

    Note: Individual diabetes regimens will be reviewed by Investigator and may be adjusted based on American Diabetes Association guidelines.

  4. Presence of cirrhosis on liver (Stage 4 fibrosis) or imaging.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
142 participants (actual)

Study arms

  • Experimental
    TVB-2640 25 mg (US)

    Subjects randomly assigned to receive the study drug will take TVB-2640 tablet orally every day for 12 week treatment period. The dose is to be taken at the same time of the day, with each dose separated by 24 hours (±4 hours).

    Drug: TVB-2640 25 mg (US)

  • Experimental
    TVB-2640 50 mg (US)

    Subjects randomly assigned to receive the study drug will take TVB-2640 tablet orally every day for 12 week treatment period. The dose is to be taken at the same time of the day, with each dose separated by 24 hours (±4 hours).

    Drug: TVB-2640 50 mg (US)

  • Placebo comparator
    Placebo (US)

    Subjects randomly assigned to placebo will receive placebo tablets orally once a day under the same conditions and frequency as described for TVB-2640.

    Drug: Placebo (US)

  • Experimental
    TVB-2640 50 mg (China)

    Subjects randomly assigned to receive the study drug will take TVB-2640 tablet orally every day for 12 week treatment period. The dose is to be taken at the same time of the day, with each dose separated by 24 hours (±4 hours).

    Drug: TVB-2640 50 mg (China)

  • Placebo comparator
    Placebo (China)

    Subjects randomly assigned to placebo will receive placebo tablets orally once a day under the same conditions and frequency as described for TVB-2640.

    Drug: Placebo (China)

  • Experimental
    TVB-2640 75 mg (US)

    After completion of Cohorts 1 and 2, and if no stopping criteria are met upon review by the Independent SRC, an additional TVB-2640 75 mg open-label Cohort 3 will open in the US

    Drug: TVB-2640 75 mg (US)

Interventions

06

What researchers measure

Primary outcomes

  1. Percent Change in Hepatic Fat Fraction by Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) From Baseline

    As determined by MRI-PDFF

    Time frame: 12 weeks

Secondary outcomes

  1. Percentage of Subjects With at Least a 30% Reduction in Liver Fat at Week 12.

    As determined by MRI-PDFF

    Time frame: 12 weeks

  2. Percentage of Change From Baseline in Alanine Aminotransferase (ALT)

    Time frame: 12 weeks

07

Results

Posted Dec 19, 2024

Participant flow

Participant flow — Overall Study
MilestoneTVB-2640 25 mg (US)TVB-2640 50 mg (US)Placebo (US)TVB-2640 50 mg (China)Placebo (China)TVB-2640 75 mg (US)
Started33353121913
Completed27303120911
Not completed650102

Outcome measures

PrimaryPercent Change in Hepatic Fat Fraction by Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) From Baseline

As determined by MRI-PDFF

Time frame:
12 weeks
Reported as:
Mean · percent change from baseline
Percent Change in Hepatic Fat Fraction by Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) From Baseline
percent change from baselineTVB-2640 25 mg (US)TVB-2640 50 mg (US)Placebo (US)TVB-2640 50 mg (China)Placebo (China)TVB-2640 75 mg (US)
Percent Change in Hepatic Fat Fraction by Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) From Baseline-11.31 ± 29.837-27.59 ± 28.3542.52 ± 33.030-28.68 ± 22.265-15.63 ± 30.789-35.77 ± 23.736
SecondaryPercentage of Subjects With at Least a 30% Reduction in Liver Fat at Week 12.

As determined by MRI-PDFF

Time frame:
12 weeks
Reported as:
Count of participants · Participants
Percentage of Subjects With at Least a 30% Reduction in Liver Fat at Week 12.
ParticipantsTVB-2640 25 mg (US)TVB-2640 50 mg (US)Placebo (US)TVB-2640 50 mg (China)Placebo (China)TVB-2640 75 mg (US)
Percentage of Subjects With at Least a 30% Reduction in Liver Fat at Week 12.71631024
SecondaryPercentage of Change From Baseline in Alanine Aminotransferase (ALT)
Time frame:
12 weeks
Reported as:
Mean · percentage of change
Percentage of Change From Baseline in Alanine Aminotransferase (ALT)
percentage of changeTVB-2640 25 mg (US)TVB-2640 50 mg (US)Placebo (US)TVB-2640 50 mg (China)Placebo (China)TVB-2640 75 mg (US)
Percentage of Change From Baseline in Alanine Aminotransferase (ALT)-2.98 ± 38.443-20.46 ± 25.9356.82 ± 37.258-28.29 ± 34.49514.06 ± 79.621-3.296 ± 42.5397

Adverse events

Collected over 12 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TVB-2640 25 mg (US)0/33 (0%)0/33 (0%)25/33 (75.8%)
TVB-2640 50 mg (US)0/35 (0%)0/35 (0%)14/35 (40%)
Placebo (US)0/31 (0%)0/31 (0%)12/31 (38.7%)
TVB-2640 50 mg (China)0/21 (0%)0/21 (0%)17/21 (81%)
Placebo (China)0/9 (0%)0/9 (0%)5/9 (55.6%)
TVB-2640 75 mg (US)0/13 (0%)0/13 (0%)9/13 (69.2%)
Most frequent other events
Showing 10 of 35
Most frequent other events
EventTVB-2640 25 mg (US)TVB-2640 50 mg (US)Placebo (US)TVB-2640 50 mg (China)Placebo (China)TVB-2640 75 mg (US)
Dry EyeEye disorders1/331/351/318/212/95/13
Skin exfoliationSkin and subcutaneous tissue disorders0/330/350/317/210/90/13
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders0/330/350/313/210/93/13
Diffuse alopeciaSkin and subcutaneous tissue disorders0/330/350/310/210/93/13
HeadacheNervous system disorders4/332/352/310/210/92/13
Abdominal distensionGastrointestinal disorders2/330/351/310/210/92/13
ConstipationGastrointestinal disorders1/331/351/310/210/92/13
Upper respiratory tract infectionInfections and infestations2/332/351/313/211/90/13
AsthenopiaEye disorders0/330/350/310/211/90/13
Conjunctival depositEye disorders0/330/350/310/211/90/13

Baseline characteristics

The overall number of participants that are provided here are as per safety population. Note- The Safety Population consisted of all randomized subjects who received at least 1 dose of study drug. Analysis is based on randomized treatment group.

Age, Categorical
Age, Categorical(Participants)TVB-2640 25 mg (US)TVB-2640 50 mg (US)Placebo (US)TVB-2640 50 mg (China)Placebo (China)TVB-2640 75 mg (US)Total
<=18 years0000000
Between 18 and 65 years27292719812122
>=65 years66421120
Sex: Female, Male
Sex: Female, Male(Participants)TVB-2640 25 mg (US)TVB-2640 50 mg (US)Placebo (US)TVB-2640 50 mg (China)Placebo (China)TVB-2640 75 mg (US)Total
Female15131743557
Male182214176885
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TVB-2640 25 mg (US)TVB-2640 50 mg (US)Placebo (US)TVB-2640 50 mg (China)Placebo (China)TVB-2640 75 mg (US)Total
Hispanic or Latino222425001384
Not Hispanic or Latino11116219058
Unknown or Not Reported0000000
Region of Enrollment
Region of Enrollment(participants)TVB-2640 25 mg (US)TVB-2640 50 mg (US)Placebo (US)TVB-2640 50 mg (China)Placebo (China)TVB-2640 75 mg (US)Total
United States3335310013112
China000219030
08

Study locations

23 sites
  • ProSciento
    Chula Vista, California 91911, United States
  • Catalina Research Institute
    Montclair, California 91763, United States
  • Clinical Trials Research
    Sacramento, California 95821, United States
  • University of California San Diego (UCSD)
    San Diego, California 92037, United States
  • Panax
    Miami Lakes, Florida 33014, United States
  • Lucas Research
    Morehead City, North Carolina 28557, United States
  • Texas Diabetes and Endocrinology - Austin
    Austin, Texas 78749, United States
  • Texas Digestive Disease Consultants - Cedar Park
    Cedar Park, Texas 78613, United States
  • Texas Digestive Disease Consultants - Dallas
    Dallas, Texas 75246, United States
  • Texas Digestive Disease Consultant - Ft Worth
    Fort Worth, Texas 76104, United States
  • Pinnacle Clinical Research - San Antonio
    San Antonio, Texas 78229, United States
  • Texas Digestive Disease Consultants - Webster
    Webster, Texas 77598, United States
  • Beijing Friendship Hospital, Capital Medical University
    Beijing, Beijing 100069, China
  • Beijing YouAn Hospital, Capital Medical University
    Beijing, Beijing 100069, China
  • Foshan First People's Hospital
    Foshan, Guangdong 528000, China
  • Nanfang Hospital
    Guangzhou, Guangdong 510080, China
  • The First Affiliated Hospital, Sun Yat-Sen University
    Guangzhou, Guangdong 510080, China
  • The Third Affiliated Hospital, Sun Yat-Sen University
    Guangzhou, Guangdong 510080, China
  • The Second Hospital of Nanjing
    Nanjing, Jiangsu 210000, China
  • Ruijin Hospital, Shanghai JiaoTong University School of Medicine
    Shanghai, Shanghai 200336, China
  • Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine
    Shanghai, Shanghai 200336, China
  • Shanghai Tongren Hospital, Shanghai JiaoTong University School of Medicine
    Shanghai, Shanghai 200336, China
  • The Affiliated Hospital of Hangzhou Normal University
    Hangzhou, Zhejiang 310015, China
09

References and documents

Publications

  • Loomba R, Mohseni R, Lucas KJ, Gutierrez JA, Perry RG, Trotter JF, Rahimi RS, Harrison SA, Ajmera V, Wayne JD, O'Farrell M, McCulloch W, Grimmer K, Rinella M, Wai-Sun Wong V, Ratziu V, Gores GJ, Neuschwander-Tetri BA, Kemble G. TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. Gastroenterology. 2021 Nov;161(5):1475-1486. doi: 10.1053/j.gastro.2021.07.025. Epub 2021 Jul 23. PubMed 34310978 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Oct 2021, 30 months.

Results were first posted in Dec 2024, 3 years 2 months after primary completion.

Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 30 months is above that.

Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2019
First posted
May 6, 2019
StartActual
Mar 22, 2019
Primary completionActual
Oct 2, 2021
CompletionActual
Oct 2, 2021
Results first posted
Dec 19, 2024
Last update
Dec 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03938246
Lead sponsor
Sagimet Biosciences Inc.
Responsible party
Sponsor
First posted
May 6, 2019
Start date
Mar 22, 2019
Primary completion
Oct 2, 2021
Completion
Oct 2, 2021
Results posted
Dec 19, 2024
Last update
Dec 19, 2024

Study contacts

Rohit Loomba, MD
principal investigator · UCSD

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TVB-2640

Start the discussion